Low dose sequential methotrexate and 5-fluorouracil administration is effective and safe as neo-adjuvant chemotherapy in oral cancer

Jun-Ichi Asaumi, Katsumi Nishijima

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We report on the effects and complications associated with low dose sequential methotrexate (MTX) and 5-fluorouracil (5-FU) (MF therapy) as neo-adjuvant chemotherapy in oral cancer. The oral cancer of 19 patients was treated as follows: MTX (75 mg/body) was administered by intravenous infusion for 1 hour, followed by 5-FU (500 mg/body) intravenous infusion for 2 hours, on Day 1, MTX (75 mg/body) intravenous infusion for 1 hour on Day 4, and parenteral dose of leucovorin on Day 2 and Day 5. A complete response was attained in one patient and a partial response in 11 patients. Complications observed were: increased serum transaminase levels (4), leucopenia (3), nausea or vomiting (4), anemia (1). The MF therapy of 2-8 courses was performed weekly or every 2 weeks. The volume in tumors of all cases decreased. Toxicity was extremely mild and radiotherapy or operation could be added sequentially without increased toxicity. These results suggests that MF therapy is effective and safety as neo-adjuvant chemotherapy before radiation and surgery for patients in oral cancer.

Original languageEnglish
Pages (from-to)559-562
Number of pages4
JournalIn Vivo
Volume10
Issue number6
Publication statusPublished - 1996

Fingerprint

Chemotherapy
Mouth Neoplasms
Adjuvant Chemotherapy
Methotrexate
Fluorouracil
Intravenous Infusions
Toxicity
Leucovorin
Radiotherapy
Transaminases
Surgery
Tumors
Leukopenia
Tumor Burden
Nausea
Vomiting
Radiation
Anemia
Therapeutics
Safety

Keywords

  • Low dose
  • Neo-adjuvant chemotherapy
  • Oral cancer
  • Sequential methotrexate and 5-fluorouracil

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Low dose sequential methotrexate and 5-fluorouracil administration is effective and safe as neo-adjuvant chemotherapy in oral cancer. / Asaumi, Jun-Ichi; Nishijima, Katsumi.

In: In Vivo, Vol. 10, No. 6, 1996, p. 559-562.

Research output: Contribution to journalArticle

@article{0d89bfd084674165bfb1e40e63fa888d,
title = "Low dose sequential methotrexate and 5-fluorouracil administration is effective and safe as neo-adjuvant chemotherapy in oral cancer",
abstract = "We report on the effects and complications associated with low dose sequential methotrexate (MTX) and 5-fluorouracil (5-FU) (MF therapy) as neo-adjuvant chemotherapy in oral cancer. The oral cancer of 19 patients was treated as follows: MTX (75 mg/body) was administered by intravenous infusion for 1 hour, followed by 5-FU (500 mg/body) intravenous infusion for 2 hours, on Day 1, MTX (75 mg/body) intravenous infusion for 1 hour on Day 4, and parenteral dose of leucovorin on Day 2 and Day 5. A complete response was attained in one patient and a partial response in 11 patients. Complications observed were: increased serum transaminase levels (4), leucopenia (3), nausea or vomiting (4), anemia (1). The MF therapy of 2-8 courses was performed weekly or every 2 weeks. The volume in tumors of all cases decreased. Toxicity was extremely mild and radiotherapy or operation could be added sequentially without increased toxicity. These results suggests that MF therapy is effective and safety as neo-adjuvant chemotherapy before radiation and surgery for patients in oral cancer.",
keywords = "Low dose, Neo-adjuvant chemotherapy, Oral cancer, Sequential methotrexate and 5-fluorouracil",
author = "Jun-Ichi Asaumi and Katsumi Nishijima",
year = "1996",
language = "English",
volume = "10",
pages = "559--562",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Low dose sequential methotrexate and 5-fluorouracil administration is effective and safe as neo-adjuvant chemotherapy in oral cancer

AU - Asaumi, Jun-Ichi

AU - Nishijima, Katsumi

PY - 1996

Y1 - 1996

N2 - We report on the effects and complications associated with low dose sequential methotrexate (MTX) and 5-fluorouracil (5-FU) (MF therapy) as neo-adjuvant chemotherapy in oral cancer. The oral cancer of 19 patients was treated as follows: MTX (75 mg/body) was administered by intravenous infusion for 1 hour, followed by 5-FU (500 mg/body) intravenous infusion for 2 hours, on Day 1, MTX (75 mg/body) intravenous infusion for 1 hour on Day 4, and parenteral dose of leucovorin on Day 2 and Day 5. A complete response was attained in one patient and a partial response in 11 patients. Complications observed were: increased serum transaminase levels (4), leucopenia (3), nausea or vomiting (4), anemia (1). The MF therapy of 2-8 courses was performed weekly or every 2 weeks. The volume in tumors of all cases decreased. Toxicity was extremely mild and radiotherapy or operation could be added sequentially without increased toxicity. These results suggests that MF therapy is effective and safety as neo-adjuvant chemotherapy before radiation and surgery for patients in oral cancer.

AB - We report on the effects and complications associated with low dose sequential methotrexate (MTX) and 5-fluorouracil (5-FU) (MF therapy) as neo-adjuvant chemotherapy in oral cancer. The oral cancer of 19 patients was treated as follows: MTX (75 mg/body) was administered by intravenous infusion for 1 hour, followed by 5-FU (500 mg/body) intravenous infusion for 2 hours, on Day 1, MTX (75 mg/body) intravenous infusion for 1 hour on Day 4, and parenteral dose of leucovorin on Day 2 and Day 5. A complete response was attained in one patient and a partial response in 11 patients. Complications observed were: increased serum transaminase levels (4), leucopenia (3), nausea or vomiting (4), anemia (1). The MF therapy of 2-8 courses was performed weekly or every 2 weeks. The volume in tumors of all cases decreased. Toxicity was extremely mild and radiotherapy or operation could be added sequentially without increased toxicity. These results suggests that MF therapy is effective and safety as neo-adjuvant chemotherapy before radiation and surgery for patients in oral cancer.

KW - Low dose

KW - Neo-adjuvant chemotherapy

KW - Oral cancer

KW - Sequential methotrexate and 5-fluorouracil

UR - http://www.scopus.com/inward/record.url?scp=0030481578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030481578&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 559

EP - 562

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 6

ER -